Drug-induced parkinsonism

被引:36
作者
Susatia, Frandy [1 ]
Fernandez, Hubert H. [1 ]
机构
[1] McKnight Brain Inst, Gainesville, FL 32610 USA
关键词
MOVEMENT-DISORDERS; RATING-SCALE; EXTRAPYRAMIDAL SYNDROMES; RECEPTOR OCCUPANCY; INDUCED PSYCHOSIS; DOUBLE-BLIND; DISEASE; CLOZAPINE; ANTIPSYCHOTICS; DOPAMINE;
D O I
10.1007/s11940-009-0019-3
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Drug-induced parkinsonism (DIP) is condition that mimics Parkinson's disease. Characterized mainly by rigidity and bradykinesia, it has less prominent tremor and gait instability. DIP is generally caused by lipophilic drugs that "block" dopamine D2 receptors in the brain, although presynaptic dopamine depletion, false transmitters, mitochondrial respiratory chain dysfunction, and overactivity in the gamma-aminobutyric acid (GABA)ergic system or cholinomimetic action have also been postulated as possible mechanisms. The onset of DIP is acute to subacute. It is more common in women and has a bimodal age distribution. Other diseases that can resemble DIP include neuropsychiatric conditions (eg, depression, negative symptoms of schizophrenia) and Wilson's disease. Physicians may be able to prevent DIP by prescribing neuroleptic agents appropriately and with caution. The risk of DIP is presumably lower with the use of "atypical" antipsychotic agents but it is not eliminated, especially in those most vulnerable to parkinsonism (eg, the elderly or cognitively impaired). The best treatment is discontinuation of the provoking medication. Prospective studies are needed to further define the mechanism of DIP, identify individual susceptibility, determine the impact of atypical antipsychotic agents, and develop further treatment options for those unable to stop the offending agent.
引用
收藏
页码:162 / 169
页数:8
相关论文
共 62 条
[11]   Ziprasidone in Parkinson's disease psychosis [J].
Connemann, BJ ;
Schönfeldt-Lecuona, C .
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2004, 49 (01) :73-73
[12]   Prevalence of parkinsonism and Parkinson's disease in Europe: The EUROPARKINSON collaborative study [J].
deRijk, MC ;
Tzourio, C ;
Breteler, MMB ;
Dartigues, JF ;
Amaducci, L ;
LopezPousa, S ;
ManubensBertran, JM ;
Alperovitch, A ;
Rocca, WA .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1997, 62 (01) :10-15
[13]  
Ebadi M, 1995, PHARMACOL REV, V47, P575
[14]   Failure of recognition of drug-induced parkinsonism in the elderly [J].
Esper, Christine D. ;
Factor, Stewart A. .
MOVEMENT DISORDERS, 2008, 23 (03) :401-404
[15]  
Factor SA, 2001, MOVEMENT DISORD, V16, P135, DOI 10.1002/1531-8257(200101)16:1<135::AID-MDS1006>3.0.CO
[16]  
2-Q
[17]  
FANN WE, 1976, AM J PSYCHIAT, V133, P940
[18]   Aripiprazole for drug-induced psychosis in Parkinson disease: Preliminary experience [J].
Fernandez, HH ;
Trieschmann, ME ;
Friedman, JH .
CLINICAL NEUROPHARMACOLOGY, 2004, 27 (01) :4-5
[19]   Long-term outcome of quetiapine use fox psychosis among Parkinsonian patients [J].
Fernandez, HH ;
Trieschmann, ME ;
Burke, MA ;
Jacques, C ;
Friedman, JH .
MOVEMENT DISORDERS, 2003, 18 (05) :510-514
[20]  
Ganzini L, 1991, J Geriatr Psychiatry Neurol, V4, P222, DOI 10.1177/089198879100400408